Matthew Oberley, Chief Clinical Officer at Caris Life Sciences, shared a post on LinkedIn:
“The FDA has updated the label for capecitabine to explicitly recommend testing for variants in the DPYD gene before starting treatment to identify patients with rare genotypes that produce versions of the enzyme DPD that have trouble with normal metabolism of capecitabine and can lead to serious side effects.
Caris Life Sciences includes DPYD testing with our therapy selection liquid biopsy Caris Assure on every patient. Please join us December 10th for an upcoming webinar with experts Bryan Krock, PhD FACMG and Jai Patel to discuss the latest developments pertaining to testing and therapy for patients with DPD deficiency.”
More posts featuring Matthew Oberley on OncoDaily.